Background Our previous research found that structural changes of the microtubule network influence glycolysis in cardiomyocytes by regulating the hypoxia-inducible factor (HIF)-1α during the early stages of hypoxia. However, little is known about the underlying regulatory mechanism of the changes of HIF-1α caused by microtubule network alternation. The von Hippel-Lindau tumor suppressor protein (pVHL), as a ubiquitin ligase, is best understood as a negative regulator of HIF-1α. Methodology/Principal Findings In primary rat cardiomyocytes and H9c2 cardiac cells, microtubule-stabilization was achieved by pretreating with paclitaxel or transfection of microtubule-associated protein 4 (MAP4) overexpression plasmids and microtubule–depolymerization was achieved by pretreating with colchicine or transfection of MAP4 siRNA before hypoxia treatment. Recombinant adenovirus vectors for overexpressing pVHL or silencing of pVHL expression were constructed and transfected in primary rat cardiomyocytes and H9c2 cells. With different microtubule-stabilizing and -depolymerizing treaments, we demonstrated that the protein levels of HIF-1α were down-regulated through overexpression of pVHL and were up-regulated through knockdown of pVHL in hypoxic cardiomyocytes. Importantly, microtubular structure breakdown activated p38/MAPK pathway, accompanied with the upregulation of pVHL. In coincidence, we found that SB203580, a p38/MAPK inhibitor decreased pVHL while MKK6 (Glu) overexpression increased pVHL in the microtubule network altered-hypoxic cardiomyocytes and H9c2 cells. Conclusions/Significance This study suggests that pVHL plays an important role in the regulation of HIF-1α caused by the changes of microtubular structure and the p38/MAPK pathway participates in the process of pVHL change following microtubule network alteration in hypoxic cardiomyocytes.
References
[1]
Kyriakides ZS, Kremastinos DT, Michelakakis NA, Matsakas EP, Demovelis T, et al. (1991) Coronary collateral circulation in coronary artery disease and systemic hypertension. Am J Cardiol 67: 687–690.
[2]
Horwitz LD, Fennessey PV, Shikes RH, Kong Y (1994) Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation 89: 1792–1801.
[3]
Huang YS, Li ZQ, Yang ZC (2003) Roles of ischemia and hypoxia and the molecular pathogenesis of post-burn cardiac shock. Burns 29: 828–833.
[4]
Huang YS, Zhang JP, Li XH (2007) A serial studies on post-burn shock heart. Burns 33: S14–S15.
[5]
Hu JY, Chu ZG, Han J, Dang YM, Yan H, et al. (2010) The p38/MAPK pathway regulates microtubule polymerization through phosphorylation of MAP4 and Op18 in hypoxic cells. Cellular and Molecular Life Sciences 67: 321–333.
[6]
Iwai K, Hori M, Kitabatake A, Kurihara H, Uchida K, et al. (1990) Disruption of microtubules as an early sign of irreversible ischemic injury. Immunohistochemical study of in situ canine hearts. Circulation Research 67: 694–706.
[7]
Teng M, Dang YM, Zhang JP, Zhang Q, Fang YD, et al. (2010) Microtubular stability affects cardiomyocyte glycolysis by HIF-1 alpha expression and endonuclear aggregation during early stages of hypoxia. American Journal of Physiology-Heart and Circulatory Physiology 298: H1919–H1931.
[8]
Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363–375.
[9]
Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L (2003) Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J Biol Chem 278: 7445–7452.
[10]
Sato H, Nagai T, Kuppuswamy D, Narishige T, Koide M, et al. (1997) Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol 139: 963–973.
[11]
Fang YD, Xu X, Dang YM, Zhang YM, Zhang JP, et al. (2011) MAP4 Mechanism that Stabilizes Mitochondrial Permeability Transition in Hypoxia: Microtubule Enhancement and DYNLT1 Interaction with VDAC1. Plos One 6: e28052.
[12]
Turcotte S, Desrosiers RR, Beliveau R (2004) Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol Renal Physiol 286: F338–348.
[13]
Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, et al. (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97: 10430–10435.
[14]
Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, et al. (1999) Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 96: 12436–12441.
[15]
Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52: 43–47.
[16]
Sufan RI, Moriyama EH, Mariampillai A, Roche O, Evans AJ, et al. (2009) Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. EMBO Mol Med 1: 66–78.
[17]
Miro-Murillo M, Elorza A, Soro-Arnaiz I, Albacete-Albacete L, Ordonez A, et al. (2011) Acute Vhl Gene Inactivation Induces Cardiac HIF-Dependent Erythropoietin Gene Expression. Plos One 6: e22589.
[18]
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275.
[19]
Yu F, White SB, Zhao Q, Lee FS (2001) HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 98: 9630–9635.
[20]
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468–472.
[21]
Gundersen GG, Cook TA (1999) Microtubules and signal transduction. Curr Opin Cell Biol 11: 81–94.
[22]
Yang Y, Zhu X, Chen Y, Wang X, Chen R (2007) p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in colchicine-induced cortical neurons apoptosis. Eur J Pharmacol 576: 26–33.
[23]
Subbaramaiah K, Hart JC, Norton L, Dannenberg AJ (2000) Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 275: 14838–14845.
[24]
Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M (2001) The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Experimental Cell Research 268: 84–92.
[25]
Khandrika L, Lieberman R, Koul S, Kumar B, Maroni P, et al. (2009) Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene 28: 1248–1260.
[26]
Caretti A, Morel S, Milano G, Fantacci M, Bianciardi P, et al. (2007) Heart HIF-1alpha and MAP kinases during hypoxia: are they associated in vivo? Exp Biol Med (Maywood) 232: 887–894.
[27]
Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ (1996) MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Molecular & Cellular Biology 16: 1247–1255.
[28]
Risinger AL, Giles FJ, Mooberry SL (2009) Microtubule dynamics as a target in oncology. Cancer Treatment Reviews 35: 255–261.
[29]
Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, et al. (1991) Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circulation Research 69: 1476–1486.
[30]
Zordoky BN, El-Kadi AO (2007) H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56: 317–322.
[31]
Cassimeris L (1999) Accessory protein regulation of microtubule dynamics throughout the cell cycle. Curr Opin Cell Biol 11: 134–141.
[32]
Ke QD, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Molecular Pharmacology 70: 1469–1480.
[33]
Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14: 1983–1991.
[34]
Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, et al. (2008) EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7: 2409–2417.
[35]
Di Cristofano C, Minervini A, Menicagli M, Salinitri G, Bertacca G, et al. (2007) Nuclear expression of hypoxia-inducible factor-1 alpha in clear cell renal cell carcinoma is involved in tumor progression. American Journal of Surgical Pathology 31: 1875–1881.
[36]
Frew IJ, Krek W (2007) Multitasking by pVHL in tumour suppression. Current Opinion in Cell Biology 19: 685–690.
[37]
Czyzyk-Krzeska MF, Meller J (2004) von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends in Molecular Medicine 10: 146–149.
[38]
Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464–468.
[39]
Haase VH (2006) The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int 69: 1302–1307.
[40]
Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, et al. (2002) Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 296: 1886–1889.
[41]
del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, et al. (2003) The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 278: 48690–48695.
[42]
Cai Q, Verma SC, Kumar P, Ma M, Robertson ES (2010) Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. Plos One 5: e9720.
[43]
Cai QL, Robertson ES (2010) Ubiquitin/SUMO Modification Regulates VHL Protein Stability and Nucleocytoplasmic Localization. Plos One 5: e12636.
[44]
Ampofo E, Kietzmann T, Zimmer A, Jakupovic M, Montenarh M, et al. (2010) Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. Int J Biochem Cell Biol 42: 1729–1735.
[45]
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, et al. (2001) Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20: 147–155.
[46]
Suomalainen M, Nakano MY, Boucke K, Keller S, Greber UF (2001) Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. EMBO J 20: 1310–1319.
[47]
Cvetkovic I, Miljkovic D, Vuckovic O, Harhaji L, Nikolic Z, et al. (2004) Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB. Cellular and Molecular Life Sciences 61: 1167–1175.
[48]
Weidemann A, Johnson RS (2008) Biology of HIF-1 alpha. Cell Death and Differentiation 15: 621–627.
[49]
Czibik G, Martinov V, Ruusalepp A, Sagave J, Skare O, et al. (2009) In vivo remote delivery of DNA encoding for hypoxia-inducible factor 1 alpha reduces myocardial infarct size. Clin Transl Sci 2: 33–40.
[50]
Czibik G, Gravning J, Martinov V, Ishaq B, Knudsen E, et al. (2011) Gene therapy with hypoxia-inducible factor 1 alpha in skeletal muscle is cardioprotective in vivo. Life Sci 88: 543–550.
[51]
Xiao J, Cao H, Liang D, Liu Y, Zhang H, et al. (2011) Taxol, a microtubule stabilizer, prevents ischemic ventricular arrhythmias in rats. J Cell Mol Med 15: 1166–1176.
[52]
Vandroux D, Schaeffer C, Tissier C, Lalande A, Bes S, et al. (2004) Microtubule alteration is an early cellular reaction to the metabolic challenge in ischemic cardiomyocytes. Molecular and cellular biochemistry 258: 99–108.
[53]
Zhang JP, Liang WY, Luo ZH, Yang ZC, Chan HC, et al. (2007) Involvement of p38 map kinase in burn-induced degradation of membrane phospholipids and upregulation of cPLA(2) in cardiac myocytes. Shock 28: 86–93.
[54]
Webster DR (1997) Regulation of post-translationally modified microtubule populations during neonatal cardiac development. Journal of molecular and cellular cardiology 29: 1747–1761.